Company intelligence / Profile preview

Cartela AB

Lund, Skåne, Sweden

Ownership: Private
Development stage: Other

Overview

Cartela AB is a Lund, Sweden-based biotech company focused on integrin research, specifically targeting the collagen-binding integrins alpha-10 and alpha-11 present on connective tissue cells. The company's lead program is a preclinical monoclonal antibody targeting integrin alpha-10 beta-1 (α10β1) for rheumatoid arthritis[1][2].

Therapeutic areas: Immunology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Cartela AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cartela AB.

Explore the full profile